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Abstract: Although high rates of complete hematologic and cytogenetic remission have 
been observed in patients with chronic phase chronic myeloid leukemia (CML) treated with 
imatinib, a short duration of response with eventual emergence of imatinib resistance has also 
been reported in a subset of CML patients. The most frequent clinically relevant mechanisms 
that change imatinib sensitivity in BCR-ABL-transformed cells are mutations within the Abl 
kinase domain, affecting several of its properties. Crystal structure analysis of the Abl-imatinib 
complex has proven helpful in identifying potential critical residues that hinder interactions of 
imatinib with mutated Abl. This has led to the development of a second generation of targeted 
therapies such as nilotinib and dasatinib, already in phase II clinical trials or SKI-606 and 
MK-0457 in phase I trials. In this review, we discuss the activity of nilotinib, developed by 
Novartis using a rational drug design strategy in which imatinib served as the lead compound. 
Preliminary studies demonstrated that nilotinib has more effi cacy than imatinib in inhibiting 
proliferation of BCR-ABL-dependent cells, a relatively safety profi le and clinical effi cacy in 
all phases of CML.
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Introduction
In the last 5 years many clinical studies have demonstrated that imatinib, the fi rst 
tyrosine kinase inhibitor introduced in the treatment of chronic myeloid leukemia 
(CML) (Olsson-Stromberg et al) has high level of activity, low toxicity, and ongoing 
durability (Druker et al 2001; O’Brien and Deininger 2003; Baccarani et al 2004; 
Kantarjian et al 2004). Its effi cacy is mainly observed in newly diagnosed patients with 
chronic phase CML, where complete hematological and cytogenetic responses where 
achieved in about 98% and in more than 80% of cases, respectively (Hughes et al 
2003; Muller et al 2003; Kantarjian et al 2006c). The fi ndings of the 5-year update of 
the International Randomised Study of Interferon versus STI571 (IRIS) comparing 
the effi cacy of imatinib 400 mg/day with interferon-alpha (IFNα) + ara-c in newly 
diagnosed patients with chronic phase CML showed an estimated rate of complete 
cytogenetic response (CCR) of 87% and an overall survival rate of 89% at 60 months 
(Druker et al 2006). With similar follow-up for patients initially studied in “late chronic 
phase” disease with intolerance or failure during prior IFN, CCR was achieved in 53%, 
refl ecting the remarkable ability of imatinib to salvage such patients (Iacobucci et al 
2006). Although the rates of progression for patients with chronic phase CML treated 
with imatinib remain low, a subset of patients develops resistance to this drug. The 
most common mechanism of resistance is the expansion of a clone of leukemic cells 
with a mutation in the kinase domain of Bcr-Abl (Branford et al 2002; Shah 2005; 
Soverini et al 2005; Branford and Hughes 2006). This mutant clone is partially or 
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totally imatinib resistant because of the reduced capacity to 
imatinib to bind to the mutant Bcr-Abl protein. Therapeutic 
options in cases of imatinib resistance include increasing the 
dose of imatinib, switching to a second generation Abl kinase 
inhibitor and proceeding to an allogenic stem cell transplant. 
In this review, we focus on the characterization of nilotinib, 
a novel, oral tyrosine kinase inhibitor developed from its 
parent compound, imatinib, and we discuss its current status 
in clinical trials.
Mechanisms of imatinib resistance
Depending on the time of onset, two categories of resistance 
can be distinguished: if there is no response after initial 
treatment, resistance is described as primary or intrinsic, 
in contrast, secondary or extrinsic resistance refers to loss 
of a previously established response (Hochhaus 2003). The 
rate of all progression events, including hematologic and 
cytogenetic relapse within chronic phase and transformation 
to advanced phase is 18% after a median of 5 years (Mauro 
2006). Although the molecular mechanisms responsible for 
the rare cases of primary resistance remain poor, the mecha-
nisms of secondary resistance are largely understood. In the 
majority of cases, resistance is caused by reactivation of 
BCR-ABL tyrosine kinase activity due to the emergence of 
specifi c point mutations within several critical regions of the 
Abl kinase domain (Hochhaus et al 2002; Shah et al 2002; 
Branford et al 2003; Soverini et al 2006). Such mutations 
impair imatinib binding either by affecting critical contact 
residues or by inducing a BCR-ABL conformation to which 
imatinib is unable to bind. More than 40 different point muta-
tions encoding for distinct single amino acid substitutions in 
the Bcr-Abl kinase domain have been identifi ed in relapsed 
CML patients. Different mutants seem to have different 
degrees of resistance to imatinib: in vitro data indicate that 
while some mutations might be overcome by dose escala-
tion (O’Hare et al 2006), others confer a highly resistant 
phenotype, thereby suggesting withdrawal of imatinib in 
favor of alternative therapeutic strategies. Indeed, since 
resistance often coincides with reactivation of the kinase 
activity within the leukemic clone, either Bcr-Abl itself or 
Bcr-Abl-triggered downstream signaling pathways remain 
good targets for molecular therapy.
Mechanisms of imatinib resistance that do not involve 
ABL mutations but are clinically relevant include ampli-
fication of the BCR-ABL fusion gene, transcriptional 
overexpression of Bcr-Abl, increased multi-drug resistance 
(MDR) activity (Marull and Rochat 2006; White et al 2006), 
cytogenetic progression, or possible the involvement of other 
kinases including members of the Src family (Cowan-Jacob 
et al 2004; Krause and Van Etten 2005). In patients who 
achieve a deep reduction in leukemic-cell burden, BCR-ABL 
transcripts rarely become undetectable and the disease recurs 
in most of these patients if imatinib is discontinued. This 
persistence of a molecularly detectable leukemic population 
is due to CML “stem cell resistance”, based in the ability of 
CML progenitors to exchange between a cycling and resting 
or “quiescent” state, the latter associated with minimal or 
no BCR-ABL expression and resulting lack of effect of Abl 
kinase inhibitors (Goldman and Gordon 2006).
Looking behind imatinib: nilotinib, 
a novel inhibitor of BCR-ABL
The emergence of imatinib resistance has stimulated the 
development of new kinase inhibitors that are able to over-
come or prevent the development of mechanisms of failure 
and ultimately eliminate all evidence of disease. Two of these 
inhibitors are in phase II trials: dasatinib (formerly BMS-
354825, Spricel®) (Luo et al 2006; Talpaz et al 2006; Cortes 
et al 2007; Hochhaus et al 2007; Quintas-Cardama et al 2007) 
and nilotinib (formerly AMN-107, Tasigna®). Other inhibi-
tors (SKI-606, VX-680) (Golas et al 2005; Coluccia et al 
2006; Giles et al 2007; ) are currently in phase I trials.
Nilotinib was developed by researchers at Novartis Phar-
maceuticals using a rational drug design strategy based on 
the replacement of the metylpiperazinyl group of imatinib 
and optimization of drug-like properties (Figure 1).
Like imatinib, nilotinib does not inhibit Src kinase and 
binds only to the inactive conformation of Bcr-Abl, with 
P-loop folding over the ATP-binding site, and the activation-
loop blocking the substrate binding site, to disrupt the 
ATP-phosphate-binding site and inhibit the catalytic activ-
ity of the enzyme (Weisberg et al 2006). Nilotinib makes
4 hydrogen-bond interactions with the Abl kinase domain, 
involving the pyridyl-N and the backbone-NH of Met318, 
the aniline-NH and the side chain hydroxyl of Thr315, the 
amido-NH and side chain carboxylate of Glu286, as well 
as the amido-C== O of Asp381 and a fl uorine atom in the 
trifl uoromethyl group of nilotinib (Weisberg et al 2006). 
This close interaction made changes in the core of imatinib 
prohibitive. The improvement in binding affi nity for Bcr-Abl 
maintains the ability to inhibit also Kit and PDGFR, but with 
less affi nity of imatinib (Bcr-Abl  PDGFR  Kit).
Preclinical studies
Nilotinib is approximately 30-fold more sensitive than ima-
tinib in the killing of BCR-ABL-dependent cells derived 
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from patients with CML (K562 and Ku-812F cells) and cell 
lines (32D and baF3), and it is active against 32/33 imatinib-
resistant cell lines with BCR-ABL mutations. The sensitivity 
of Bcr-Abl mutants to AMN107 can be summarized into 4 
categories: high (IC
50
  70 nmol/L: M244V, G250E, Q252H, 
F3llL, F317L, M351T, V379I, L387M, H396P, H396R), 
medium (IC
50
  200 nmol/L: Y253F, E255K, F359V), 
low (IC
50
  450 nmol/L: Y253H, E255V), and insensitive 
(IC
50
  2 µmol/L: T315I) (Table 1) (O’Hare et al 2005). 
Nilotinib does not inhibit T315I (also resistant to imatinib 
and dasatinib), due to the loss of the hydroxyl side chain and 
the introduction of the methyl group of the isoleucine in the 
“gatekeeper” region of the ATP binding site, which inhibits 
binding (Pricl et al 2005). On the other hand, M351I is more 
sensitive to nilotinib than would be predicted. This residue 
makes close contact with imatinib, but not with nilotinib, 
due to the differences in their chemical structure. Therefore, 
M351I affects the binding of imatinib, but has little effect 
on the binding of nilotinib (O’Hare et al 2005) (Table 1). In 
vivo studies demonstrated that nilotinib increased survival 
in mouse models with native Bcr-Abl and imatinib-resistant 
Bcr-Abl (Golemovic et al 2005). Nilotinib is also approxi-
mately 30–40 times more potent than imatinib in inhibiting 
the proliferation of p190 Bcr-Abl – expressing Ph-positive 
ALL cell lines and it is also consistently (more than 20 
times) more potent than imatinib in inhibiting phosphoryla-
tion of p190 Bcr-Abl kinase in these cell lines (Verstovsek 
et al 2005).
Phase I study
In a dose-escalating phase I study (Kantarjian et al 2006a), 
nilotinib was administered orally to 119 patients with 
imatinib-resistant CML or acute lymphoblastic leukemia 
(ALL) according to the following dosing schedule: 
50 mg (7 patients), 100 mg (7), 200 mg (10), 400 mg (10), 
600 mg (6), 800 mg (19), and 1200 mg (10) or to receive 
400 mg twice daily (32) or 600 mg twice daily (18). Plasma 
level saturation was observed at more than 400mg/day. 
Among 119 patients, 17 were in chronic phase disease, 56
in accelerated phase (10 with clonal evolution only), 24 in 
myeloid blast phase, 9 in lymphoid blast phase, and 13 had 
Ph-positive ALL. Signifi cant clinical activity was identi-
fi ed in all CML phases. Overall, of 33 patients with the 
blastic phase, 13 had a hematologic response to nilotinib 
(39%) and 9 patients (27%) had a cytogenetic response, 6 of 
whom had a major cytogenetic response (Ph-positive cells in 
metaphase, 35%). Of 46 patients with accelerated-phase 
CML (excluding those with clonal evolution only), 33 had a 
hematologic response and 22 had a cytogenetic response; 9 
of these responses were major. Among the 10 patients who 
had clonal evolution as the only feature of the accelerated 
phase of CML, 5 had active disease and 5 were in complete 
hematologic remission. All 5 patients with clonal evolu-
tion and hematologic disease had a complete hematologic 
response; 6 of 10 had a major cytogenetic response. Among 
17 patients with the chronic phase of disease, 11 of 12 patients 
with active disease have had a complete hematologic remis-
sion. There were cytogenetic responses in 9 of 17 patients 
who could be evaluated, including 6 responses that were 
complete. One of 10 patients with Ph-positive ALL (hema-
tologic relapse) had a partial hematologic response, and 1 
of 3 patients with Ph-positive ALL and persistent molecular 
signs of ALL had a complete molecular remission (Table 2). 
Response rates to nilotinib were similar in patients with and 
those without BCR-ABL mutations. Two patients with a 
mutation of T315I did not have a response to nilotinib, as 
predicted from preclinical studies.
The treatment was well tolerated. Most frequent grade 
3–4 adverse events were hematologic, with thrombocytope-
nia and neutropenia seen in 20% and 12%, respectively.
Imatinib Nilotinib
Figure 1 Modular structure of imatinib and nilotinib.
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Other adverse events were less frequent and were 
primarily grade 1–2. Neutropenia and indirect self-limited 
reversible hyperbilirubinemia were observed mostly at the 
dose of 600 mg twice daily. A nilotinib dose of 400 mg 
twice daily was selected for the phase II studies based on 
effi cacy and long-term side effects (Jabbour et al 2006). 
Nilotinib prolongs the QTcF interval in some patients. One 
unexplained sudden death was reported beyond the fol-
low-up time analysis (Kantarjian et al 2006a). This fi nding 
indicates the need for careful monitoring for cardiac events 
and arrhythmias in all patients who are receiving nilotinib 
and a strict avoidance of medications that may prolong the 
QTcF interval.
Phase II studies
The phase II study was designated to evaluate the safety and 
effi cacy, as defi ned by hematologic (normalization of white 
blood cell counts) and cytogenetic (reduction or elimina-
tion of the Ph+ chromosome) response rates of nilotinib 
administered to imatinib-resistant or intolerant patients with 
Ph+ CML in chronic phase, accelerated phase, blastic phase 
and Ph-positive ALL. The 316 chronic-phase patients in the 
phase II study were heavily pre-treated for Ph+ CML, with a 
signifi cant majority (72%) having received at least 600 mg of 
imatinib as well as having been treated earlier with interferon 
(65%) and hydroxyurea (83%).
Among 279 assessable patients (ie, those patients with at 
least six months of follow up) with chronic-phase disease, 
major cytogenetic response was observed in 145 (52%) of 
which 96 (34%) were complete. Complete hematologic 
response was reported in 137 (74%) of 185 assessable 
patients. In patients with at least 10 months follow-up, 
the median time to cytogenetic response was 2.8 months 
(range 1–11), and the median time to complete hematologic 
response was 1.0 (range 1–8) months (Giles et al 2006; 
le Coutre et al 2006).
Among 64 patients with accelerated-phase disease, major 
cytogenetic response was observed after at least 8 months 
follow-up in 23 patients (36%), of which 14 (22%) were 
complete. Confi rmed hematologic response occurred in 38 
(59%), of which 15 (23%) were complete. The median time 
to cytogenetic response was 2.0 months (range 1–8), and 
the median time to complete hematologic response was 1.0 
(range 1–3) months (Kantarjian et al 2006b).
Preliminary data have also been presented for 96 blast 
phase and 34 Ph-positive ALL patients. Complete hematolog-
ical response was reported in 12 (13%) blast phase patients, 
marrow response in 6 (6%), return to chronic phase and stable 
disease in 17 (18%) patient each. Complete responses were 
reported in 2 (6%) Ph+ ALL patients (1 relapsed/refractory 
and 1 with minimal residual disease) (Table 3) (Ottmann 
et al 2006).
Table 1 Comparison between imatinib, nilotinib IC50 values (nmol/L) for cellular proliferation and cellular Bcr-Abl tyrosine phos-
phorylation assay
 Ba/F3 cellular assays
 Imatinib   Nilotinib  
 Celular proliferation Bcr-Abl tyrosine Celular proliferation Bcr-Abl tyrosine
 IC50 (nmol/L) phosphorylation IC50 (nmol/L) phosphorylation
  IC50 (nmol/L)  IC50 (nmol/L)
WT Bcr-Abl 260 280 13 10
M244V 2,000 500 38 8
G250E 1,350 1,000 48 7
Q252H 1,325 1,500 70 15
F311L 480 600 23 44
F317L 1,050 400 50 47
M351T 880 500 15 8
V397I 1,630 800 51 15
L387M 1,000 2,700 49 33
H396P 850 2,700 41 70
H396R 1,750 1,000 41 22
Y253F 3,475 4,200 125 55
E255K 5,200 5,000 200 70
F359V 1,825 3,100 175 43
Y253H 6,400 5,000 450 155
E255V 6,400 5,000 430 250
T315I 6,400 5,000 2,000 5,000
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The phase II study showed an acceptable tolerability 
profi le with a low incidence of events related to fl uid 
retention such as edema, a side effect common with other 
tyrosine kinase inhibitors. The most frequent Grade 3 or 
4 adverse events were primarily hematological in nature 
and include neutropenia and thrombocytepenia. Elevations 
were seen in bilirubin, liver function tests, lipase enzymes, 
and blood sugar, which were mostly transient and resolved 
over time. These cases were easily managed and rarely 
led to discontinuation. Pancreatitis was reported in less 
than 1% of cases. The study also showed virtually no 
non-hematologic cross-intolerance between imatinib 
and nilotinib (cross-intolerance occurs when patients 
cannot tolerate two different drugs because of the same 
side effects). Causes of non-hematologic intolerance to 
imatinib, which occurred in 95 patients, included Grade 
3 or 4 rash/skin toxicity, fl uid retention, gastrointestinal 
intolerance, liver toxicity, and myalgia/arthralgia. When 
treated with nilotinib, none of these patients experienced 
severe rash/skin toxicity, fluid retention or myalgia/
arthralgia. One patient each experienced severe gastroin-
testinal intolerance and liver toxicity. Further follow-up 
of the phase II studies is ongoing.
Nilotinib as fi rst-line therapy
Based on Phase II experience, a study of nilotinib as fi rst 
line therapy for patients with CML in early chronic phase 
has been started with the objective to improve the overall 
molecular response and to achieve responses earlier since 
early achievement of response has been correlated with 
improved long-term outcome. The preliminary data in 
14 patients treated suggest that indeed the higher potency 
is translating into better responses, with 100% of patients in 
complete hematologic response after 3 months of therapy, 
and 100% of patients in complete cytogenetic response 
within 6 months. A major molecular response was achieved 
in 54% by 6 months. These responses appeared to be more 
rapid than observed with imatinib 800 mg daily (Jabbour 
et al 2006).
In addition, considering the effi cacy of nilotinib after 
failure to imatinib, there is interest in exploring earlier 
intervention in patients who have not met the criteria for 
failure but have a suboptimal response as defi ned by the 
recommendations of a panel of CML experts (Baccarani 
et al 2006).
Future strategies
There is an urgent need for the development of compounds 
active against the T315I-Bcr-Abl mutant because it might 
drive the majority of cases who acquire resistance to novel 
second-generation inhibitors. The T315I is responsible for 
approximately 15% of the cases of relapse in CML and 
Ph+ ALL patients on imatinib therapy. Structural analyses 
indicate that the substitution of threonine with isoleucine 
Table 2 Results from a phase I study: response to nilotinib in patients with imatinib resistance
Disease phase Patients Hematological response  Cytogenetic response 
 (n) Total (%) Complete (%) Total (%) Major (%)
Chronic phase CML 17 92 92 53 35
Accelerated phase CML     
Hematological disease 46 72 46 48 20
Clonal evolution only 10 100 100 90 60
Myeloid blastic phase CML 24 42 8 29 21
Lymphoid blastic phase CML 9 33 0 22 11
Abbreviations: CML, chronic myeloid leukemia.
Table 3 Results from a phase II study: response to nilotinib in patients with imatinib failure
Disease phase Patients Hematological response Cytogenetic response
 (n) Complete (%) Major (%)
Chronic phase CML 279 74 52
Accelerated phase CML 64 23 36
Blast phase CML 96 13 NA
Ph-positive ALL 34 6 NA
Abbreviations: ALL, acute lymphoblastic leukaemia; CML, chronic myeloid leukemia; NA, not available.
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at residue 315 eliminates a crucial hydrogen-bonding 
interaction and introduces a steric clash which abrogates 
binding and effective inhibition of Bcr-Abl by imatinib as 
well as by several novel inhibitors (Pricl et al 2005). A differ-
ent approach to tyrosine kinase inhibition is to design inhibi-
tors binding regions of Bcr-Abl other than the ATP binding 
pocket. This is the case of ON012380 (Gumireddy et al 
2005), which binds to the substrate binding site. ON01910 
is a similar agent that also inhibits Plk1, a kinase that plays 
a critical role in cell cycle progression. Adaphostin is a 
non-ATP competitive TKI that inhibits Bcr-Abl and induces 
apoptosis in both imatinib-sensitive and imatinib-resistant 
cell lines and acts synergistically with imatinib. Adaphostin 
also increases levels of intracellular reactive oxygen species 
and can stimulate apoptosis in Ph-negative malignant cells 
(Mow et al 2002).
An intriguing alternative is to explore the possibility of 
whether molecules that have been developed as inhibitors 
for other protein kinases and are already undergoing clinical 
trials might inhibit the T315I-Bcr-Abl mutant. MK-0457 
(VX-680) is a potent multikinase inhibitor with activity 
against aurora kinases (Carter et al 2005; Shah 2006). The 
biochemical structure of MK-0457 makes it able to bind and 
inhibit Bcr-Abl kinase despite the presence of T315I muta-
tion that prevents the inhibitory activity of all other kinase 
inhibitors tested in the clinic including imatinib, dasatinib and 
nilotinib. A phase I study of MK-0457 is being conducted 
and the preliminary analysis has shown responses in some of 
the patients with CML who had failed imatinib and had the 
T315I mutation, as well as patients with myeloproliferative 
disorders with the JAK-2 mutation. Phase II studies of this 
agent, with particular attention to these patient populations, 
are starting (Giles et al 2007).
Conclusion
Since Bcr-Abl signaling remains central to CML patho-
genesis, the selective inhibition of wild type and imatinib 
resistant Bcr-Abl signaling is still the therapeutic strategy of 
choice to overcome imatinib resistance. This approach led 
to the development of novel tyrosine kinase inhibitors more 
potent than imatinib, such as dasatinib and nilotinib. Preclini-
cal and early-phase clinical fi ndings indicate that nilotinib, 
a “cousin” of imatinib, may be useful in the treatment of 
imatinib-refractory CML, due to its strong binding affi nity to 
Abl, its activity against imatinib-resistant BCR-ABL mutants 
and its effi cacy and tolerability in clinical studies. However, 
the durability of responses remains undefi ned. Furthermore, 
nilotinib (like imatinib and dasatinib) do not overcome the 
T315I-Bcr-Abl mutation, which may drive the majority of 
acquired resistance cases to these compounds. Strategies to 
override resistance mediated by the T315I mutation repre-
sent the next major goal in the targeted treatment of CML. 
Compounds such as VX-680, an aurora kinase inhibitor, 
capable of binding to and inhibiting kinase activity of the 
T315I-Bcr-Abl mutation, are very encouraging.
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